Targeting basal-like breast cancers

Current Drug Targets

Volumn 13, Issue 12, 2012, Pages 1510-1524

  Dey, Nandini ^a   Smith, Brian R ^b   Leyland Jones, B ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b VM Institute of Research   (Canada)

Author keywords

Basal like breast cancers; BRCA1 2 incompetency; PARP inhibitors; Pathway targeted inhibitors; PTEN; Triple negative breast cancer

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; ANTHRACYCLINE; BETA CATENIN; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOKERATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EVEROLIMUS; GEMCITABINE; IMATINIB; INIPARIB; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; RUCAPARIB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VELIPARIB;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASAL LIKE BREAST CANCER; CANCER SPECIFIC SURVIVAL; EXCISION REPAIR; GASTROINTESTINAL STROMAL TUMOR; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOPHENOTYPING; METHYLATION; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84870174384     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530116     Document Type: Article

References (164)

1. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol 2010; 7(3): 139-147.
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26(15): 2568-2581.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
4. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol 2009; 20(12): 1913-1927.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-10874.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14): 8418-8423.
7. Thike AA, Iqbal J, Cheok PY, et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010; 34(7): 956-964.
8. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R. Triple-negative breast cancer. Curr Opin Oncol 2008; 20(6): 614-620.
9. Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. Clin Breast Cancer 2010; 10(3): 188-195.
10. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14(5): 1368-1376.
11. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16): 5367-5374.
12. Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L. Identification of basal-like carcinomas in clinical practice: triple zero/BRCA1-like carcinomas]. Bull Cancer 2010; 97(3): 357-363.
13. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36(3): 206-215.
14. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 2010; 121(2): 281-292.
15. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15(7): 2302-2310.
16. Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010; 16(1): 48-52.
17. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14(24): 8010-8018.
18. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res 2007; 9(5): R65.
19. Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11(4): 339-349.
20. Geyer FC, Lacroix-Triki M, Savage K, et al. Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011; 24(2): 209-231.
21. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals overrepresentation of triple-negative breast cancer. J Clin Oncol 2009;27(27): 4515-4521.
22. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 2007; 109(9): 1721-1728.
23. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-2502.
24. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 2009; 15(5): 454-460.
25. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basallike breast cancer. Breast Cancer Res Treat 2008; 109(1): 123-139.
26. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49(1): 22-34.
27. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19(2): 264-271.
28. Venkitaraman R. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther 2010; 10(2): 199-207.
29. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429-4434.
30. Gray J. Cancer: Genomics of metastasis. Nature 2010; 464(7291): 989-990.
31. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2- overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45(16): 2792-2798.
32. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8): 1275-1281.
33. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68(9): 3108-3114.
34. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19(5): 312-321.
35. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005; 7(4): 143-148.
36. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14(6): 419-430.
37. Witkiewicz AK, Dasgupta A, Sammons S, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010; 10(2): 135-143.
38. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464(7291): 999-1005.
39. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010; 141(2): 210-217.
40. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348(23): 2339-2347.
41. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26(14): 2126-2132.
42. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4(10): 814-819.
43. Sproul D, Nestor C, Culley J, et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci USA 2011; 108(11): 4364-4369.
44. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent second hit in tumors with germline BRCA mutations. Fam Cancer 2009; 8(4): 339-346.
45. Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60(19): 5329-5333.
46. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18(11): 1957-1965.
47. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92(7): 564-569.
48. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21(9): 1761-1765.
49. Beckmann MW, Picard F, An HX, et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 1996; 73(10): 1220-1226.
50. Miller BJ, Wang D, Krahe R, Wright FA. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 2003; 73(4): 748-767.
51. Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res 2003; 63(16): 4978-4983.
52. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42(5): 410-414.
53. Venkitaraman AR. A growing network of cancer-susceptibility genes. N Engl J Med 2003; 348(19): 1917-1919.
54. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004; 23(4): 1000-1004.
55. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004; 64(9): 2994-2997.
56. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003; 3(5): 417-420.
57. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9(5): 568-574.
58. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95(19): 1482-1485.
59. Collins N, Wooster R, Stratton MR. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997; 76(9): 1150-1156.
60. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115(5): 523-535.
61. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451(7182): 1111-1115.
62. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451(7182): 1116-1120.
63. Martin RW, Connell PP, Bishop DK. The Yin and Yang of treating BRCA-deficient tumors. Cell 2008; 132(6): 919-920.
64. Giuseppe T, Maria EF, Gaia S. Molecular prognostic factors: clinical implications in patients with breast cancer. Cancer Therapy 2008; 6: 773-782.
65. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105(5): 1680-1685.
66. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8(3): 193-204.
67. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7(7): 517-528.
68. Krishnakumar R, Kraus WL. The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets. Mol Cell 2010; 39(1): 8-24.
69. Arnes JB, Begin LR, Stefansson I, et al. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol 2009; 62(2): 139-146.
70. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6(1): R8-R17.
71. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18(24): 4053-4059.
72. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344(8): 539-548.
73. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28(7): 1145-1153.
74. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913-917.
75. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-921.
76. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2- deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14(12): 3916-3925.
77. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-134.
78. Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69(9): 3850-3855.
79. Rottenberg S, Jonkers J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat 2008; 11(1/2): 51-60.
80. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26(22): 3785-3790.
81. Wicha MS. Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer. Breast Cancer Res 2009; 11(5): 108.
82. Anders CK, Winer EP, Ford JM, et al. Poly(ADP-Ribose) polymerase inhibition: targeted therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16(19): 4702-4710.
83. Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treat Rev 2010.
84. Boss DS, Beijnen JH, Schellens JH. Inducing Synthetic Lethality using PARP Inhibitors. Curr Clin Pharmacol 2010.
85. Domagala P, Lubinski J, Domagala W. Iniparib in metastatic triplenegative breast cancer. N Engl J Med 2011; 364(18): 1780; author reply 1.
86. Telli ML, Ford JM. Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer 2010; 10: E16-E22.
87. Cipak L, Jantova S. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. Neoplasma 2010; 57(5): 401-405.
88. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235-244.
89. Tutt A, Robson M, Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meet Abstr) 2009; 27: CRA501.
90. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. ASCO Meet Abstr 2009; 273.
91. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52(1): 108-118.
92. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39(6): 857-865.
93. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas Nat Genet 1999; 21(2): 236-240.
94. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009; 7(8): 1304-1309.
95. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94(14): 7303-7307.
96. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells. Cancer Res 2010; 70(13): 5389-5398.
97. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22(47): 7265-7279.
98. Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010; 80(5): 647-653.
99. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105(44): 17079-17084.
100. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008; 7(12): 2010-2019.
101. Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008; 27(9): 1368-1377.
102. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1(6/7): 315-322.
103. O'Brien T, Stokoe D. Converting cancer mutations into therapeutic opportunities. EMBO Mol Med 2009; 1(6/7): 297-299.
104. McEllin B, Camacho CV, Mukherjee B, et al. PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors. Cancer Res 2010; 70(13): 5457-5464.
105. Faratian D, Bartlett J. Predictive markers in breast cancer-the future. Histopathology 2008; 52(1): 91-98.
106. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8(3): 235-244.
107. Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 2008; 19(4): 669-674.
108. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10(6): R101.
109. Parsons R, In: PTEN and PI3K pathway alterations in breast cancer. CNIO Cancer Confereance; Madrid, May 8-10, 2006.
110. Umemura S, Yoshida SYO, et al. In: Increased phosphorylation of Akt in triple-negative breast cancers: Blackwell Publishing 2007 pp1889-1892.
111. Lerma E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007; 20(11): 1200-1207.
112. Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40(1): 102-107.
113. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104(18): 7564-7569.
114. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126(5): 1121-1231.
115. Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clin Cancer Res 2009; 15(20): 6309-6310.
116. Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer 2009; 16(4): 275-280.
117. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative forHer-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005; 58(7): 700-704.
118. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009; 69(2): 565-572.
119. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009; 45 Suppl 1: 27-40.
120. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 16(1): 104-107.
121. Carey L, Mayer E, Marcom PK, et al. EGFR inhibition with cetuximab in metastatic triple negative (basallike)breast cancer Breast Cancer Res Treat 2007; 106(Suppl 1): S32.
122. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006; 37(9): 1217-1226.
123. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10(1 Pt 1): 178-183.
124. Modi S, Seidman AD, Dickler M, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005; 90(2): 157-163.
125. Roussidis AE, Mitropoulou TN, Theocharis AD, et al. STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. Anticancer Res 2004; 24(3a): 1445-1447.
126. Railo MJ, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 1994; 30A(3): 307-311.
127. Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007; 43(13): 1895-1904.
128. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5(1): 95-105.
129. Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 2000; 24(3): 199-206.
130. Yee D. Can the insulin-like growth factors regulate breast cancer growth? Breast Cancer Res Treat 1992; 22(1): 3-5.
131. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA 2009; 106(7): 2359-2364.
132. Litzenburger B, Tsimelzon A, Hilsenbeck S, et al. In: High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer, Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX. Dec 10-13, 2009.
133. Yang S, Chintapalli J, Sodagum L, et al. Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am J Physiol Renal Physiol 2005; 289(5): F1144-F1152.
134. Barnes J. IGF-1R, after a slow start this new oncology target is picking up momentum. 2007; 1(11), The Barnes Report, Nov, 5. Available from: http://www.imakenews.com/barnesreport/e_article000944565.cfm?x=b11,0,w
135. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010; 176(6): 2911-2920.
136. Barwick B, Moreno C, Dey N, et al. Wnt signaling in triple negative breast cancer is associated with poor prognosis and metastasis 2012 [epub ahead of print].
137. Abramovitz M, Catzavelos C, Li Z, et al., In: Identification of Matrix Metalloproteinase 7 (MMP7) as a Selective Biomarker of the Triple-Negative Breast Cancer Subtype. AACR Annual meeting; Denver, CO. April 18-22, 2009.
138. Dey N, Barwick B, Kerstann K, et al. In: Role of Wnt-beta-catenin pathway in the control of tumor cell migration in the triple negative subset of breast cancer. Advances in Breast Cancer Research, AACR; San Diego, 2009.
139. Dey N, Barwick B, Bouzyk M, De P, Leyland-Jones B, In: Role of Wnt-beta-catenin pathway in the control of tumor cell invasion in the triple negative subset of breast cancer, AACR Annual Meeting; Washington, DC 2010.
140. Li H, Sekine M, Tung N, Avraham HK. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin. Mol Cancer Res 2010; 8(3): 407-420.
141. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008; 19(8): 1379-1386.
142. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105(3): 319-326.
143. Choi YL, Bocanegra M, Kwon MJ, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010; 70(6): 2296-2306.
144. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov.
145. Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 2010; 16(1): 33-38.
146. Goffin JR, Straume O, Chappuis PO, et al. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003; 89(6): 1031-1034.
147. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64(3): 830-835.
148. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18(38): 5356-5362.
149. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, plateletderived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57(5): 963-969.
150. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol 2006; 125(4): 512-518.
151. Shiu KK, Tan DS, Reis-Filho JS. Development of therapeutic approaches to 'triple negative' phenotype breast cancer. Expert Opin Ther Targets 2008; 12(9): 1123-1237.
152. Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term followup. Breast Cancer Res Treat 2010; 120(2): 491-498.
153. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26(11): 1810-1816.
154. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 2007; 16 Suppl 2: S17-S19.
155. Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res 2007; 13(2 Pt 2): 777s-780s.
156. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155(3): 739-752.
157. Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol 1999; 155(3): 675-679.
158. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am J Pathol 1997; 151(5): 1417-1423.
159. Barinaga M. New type of blood vessel found in tumors. Science 1999; 285(5433): 1475.
160. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61(2): 445-451.
161. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002; 62(2): 560-566.
162. Shirakawa K, Wakasugi H, Heike Y, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99(6): 821-828.
163. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16 Suppl 1: 1-11.
164. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125(3): 627-636.